Want to see IN:VIYASH full AI Analyst Report?
VIYASH Stock Chart & Stats
₹210.65
-₹3.94(-2.00%)
At close: 4:00 PM EST
₹210.65
-₹3.94(-2.00%)
Day’s Range― - ―
52-Week Range₹166.20 - ₹297.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)119.95K
Market Cap
₹128.41B
Enterprise Value₹108.85B
Total Cash (Recent Filing)₹722.20M
Total Debt (Recent Filing)₹4.90B
Price to Earnings (P/E)90.0
Beta1.29
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.67
Shares Outstanding436,875,500
10 Day Avg. Volume209,903
30 Day Avg. Volume119,946
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.72
Price to Sales (P/S)2.32
P/FCF Ratio61.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)9.45
Revenue Forecast (FY)₹39.17B
Bulls Say, Bears Say
Bulls Say
Revenue MomentumA >100% revenue leap in 2026 signals meaningful demand recovery and scale. Sustained top-line expansion gives management room to invest in R&D, commercial scale and fixed-cost absorption, supporting durable profit improvement if growth persists beyond a single-year rebound.
Improving ProfitabilityEBIT and EBITDA margins rising to ~12% and ~19% indicate the business can convert higher revenue into operating cash flow and profits. If maintained, these margins provide structural capacity for reinvestment and resilience versus peers in the specialty/generic drugs segment.
Stronger Balance SheetMaterial deleveraging (D/E ~0.17) and equity expansion materially reduce financial risk and interest burden. A healthier capital structure improves flexibility to fund M&A, capex or R&D without over-reliance on external funding, strengthening multi-quarter stability.
Bears Say
Earnings Volatility / Past LossesThe company’s recent history includes loss years and pronounced swings in results, which undermines predictability of future earnings. Persistent execution or demand variability raises the risk that the 2026 rebound may not reflect a stable, repeatable earnings profile over the medium term.
Weak Cash ConversionFCF remains materially lower than reported net income and operating cash flow is a small share of revenue, indicating earnings are not fully translating into cash. That limits internal funding for capex, debt paydown or dividends and leaves performance sensitive to working capital swings.
Unproven Margin SustainabilityMargins recovered sharply, but prior negative EBIT and wide swings show cost structure and pricing power are not yet proven. If revenue growth moderates, margins could re-compress, exposing earnings and cash flow to downside across the next several quarters.
Viyash Scientific News
VIYASH FAQ
What was Viyash Scientific Limited’s price range in the past 12 months?
Viyash Scientific Limited lowest stock price was ₹166.20 and its highest was ₹297.00 in the past 12 months.
What is Viyash Scientific Limited’s market cap?
Viyash Scientific Limited’s market cap is ₹128.41B.
When is Viyash Scientific Limited’s upcoming earnings report date?
Viyash Scientific Limited’s upcoming earnings report date is Aug 12, 2026 which is in 38 days.
How were Viyash Scientific Limited’s earnings last quarter?
Viyash Scientific Limited released its earnings results on May 19, 2026. The company reported ₹1.17 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.17.
Is Viyash Scientific Limited overvalued?
According to Wall Street analysts Viyash Scientific Limited’s price is currently Overvalued.
Does Viyash Scientific Limited pay dividends?
Viyash Scientific Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of N/A. See more information on Viyash Scientific Limited dividends here
What is Viyash Scientific Limited’s EPS estimate?
Viyash Scientific Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Viyash Scientific Limited have?
Viyash Scientific Limited has 436,875,500 shares outstanding.
What happened to Viyash Scientific Limited’s price movement after its last earnings report?
Viyash Scientific Limited reported an EPS of ₹1.17 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.373%.
Which hedge fund is a major shareholder of Viyash Scientific Limited?
Currently, no hedge funds are holding shares in IN:VIYASH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Viyash Scientific Limited
Viyash Scientific Limited is a global veterinary healthcare company with operations spanning Europe, Asia, and other international markets. It specializes in developing and supplying finished dosage forms for a range of therapeutic applications, including nutritional support, pain relief, parasite control, antibiotic treatments, and gut health solutions. These products cater to various animals like livestock, poultry, and domestic pets. Additionally, the company extends its expertise through analytical testing and specialized veterinary formulation services. Originally established as Sequent Scientific Limited, the company officially adopted the name Viyash Scientific Limited in January 2026. Founded in 1985, its corporate headquarters are situated in Hyderabad, India. Currently, Viyash Scientific Limited functions as a subsidiary of CA Harbor Investments.
Technical Analysis
Akums Drugs and Pharmaceuticals Limited
―
Alembic Pharmaceuticals Limited
―
Caplin Point Laboratories Limited
―
Glenmark Life Sciences Limited
―
Strides Pharma Science Ltd
―